{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:48:35Z","timestamp":1792622915308,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T00:00:00Z","timestamp":1764979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharm Health Care Sci"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Advanced non-squamous non-small cell lung cancer has a poor prognosis, and immune checkpoint inhibitors (ICIs) plus platinum-based combination chemotherapy is the first-line treatment. Atezolizumab, an ICI, has three regimens: atezolizumab\u2009+\u2009carboplatin (CBDCA)\u2009+\u2009paclitaxel\u2009+\u2009bevacizumab [ABCP], atezolizumab\u2009+\u2009CBDCA\u2009+\u2009nab-paclitaxel (nab-PTX) [A\u2009+\u2009CnP], and atezolizumab\u2009+\u2009CBDCA\u2009+\u2009pemetrexed [A\u2009+\u2009CbP]. However, clinical trials directly comparing these regimens have not been reported, and the differences in adverse events have not been fully clarified.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We calculated the reporting odds ratio (ROR), a measure of adverse drug reaction (ADR) signals, using the FDA Adverse Event Reporting System (FAERS) to compare the major ADRs of ABCP, A\u2009+\u2009CnP, and A\u2009+\u2009CbP regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The ROR (95% confidence interval [CI]) for rash and hypersensitivity-related adverse events was 2.06 (1.81\u20132.34) for ABCP, 0.81 (0.42\u20131.56) for A\u2009+\u2009CnP, and 0.57 (0.37\u20130.87) for A\u2009+\u2009CbP; the signal was only detected for the ABCP regimen. In acute kidney injury (AKI), it was ABCP: 1.24 (0.89\u20131.73), A\u2009+\u2009CnP: 1.16 (0.37\u20133.60), and A\u2009+\u2009CbP: 1.76 (1.06\u20132.93), and signal was detected only for the A\u2009+\u2009CbP regimen. Contrarily, signals were detected for colitis, drug-induced liver injury, and pneumonitis for all regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Rash and hypersensitivity-related adverse events and AKI were more frequently reported with the ABCP and A\u2009+\u2009CbP regimens, respectively. These observations may help generate hypotheses regarding regimen-specific adverse event profiles and support future studies toward individualized chemotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40780-025-00522-6","type":"journal-article","created":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T10:45:19Z","timestamp":1765017919000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Disproportionality analysis of adverse events in advanced lung cancer treated with atezolizumab plus platinum-based combination chemotherapy"],"prefix":"10.1186","volume":"12","author":[{"given":"Katsuyuki","family":"Hazama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiro","family":"Tochikura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsaku","family":"Washinosu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susumu","family":"Ootsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Hanada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,6]]},"reference":[{"key":"522_CR1","doi-asserted-by":"publisher","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A, Cancer statistics. CA Cancer J. Clin. 2021 Jan 12; 71(1):7\u201333. Available from: https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/https:\/\/doi.org\/10.3322\/caac.21654.","DOI":"10.3322\/caac.21654"},{"key":"522_CR2","doi-asserted-by":"crossref","unstructured":"Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446\u2013454. Available from: https:\/\/www.nature.com\/articles\/nature25183.","DOI":"10.1038\/nature25183"},{"key":"522_CR3","doi-asserted-by":"publisher","unstructured":"Langer CJ, Besse B, Gualberto A, Brambilla E, Soria JC. The evolving role of histology in the management of advanced non-small-cell lung cancer. J Clin Oncol. 2010;28(36):5311-20. Available from: https:\/\/doi.org\/10.1200\/JCO.2010.28.8126.","DOI":"10.1200\/JCO.2010.28.8126"},{"key":"522_CR4","doi-asserted-by":"crossref","unstructured":"Arbour KC, Riely GJ. Systemic therapy for locally advanced and metastatic non-small cell lung cancer: a review. JAMA. 2019;322(8):764\u2013774. Available from: https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2748800.","DOI":"10.1001\/jama.2019.11058"},{"key":"522_CR5","doi-asserted-by":"publisher","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443-54. Available from: https:\/\/www.nejm.org\/doi\/full\/https:\/\/doi.org\/10.1056\/NEJMoa1200690.","DOI":"10.1056\/NEJMoa1200690"},{"key":"522_CR6","doi-asserted-by":"crossref","unstructured":"West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(7):924\u2013937. Available from: https:\/\/www.thelancet.com\/journals\/lanonc\/article\/PIIS1470-2045(19)30167-6\/fulltext.","DOI":"10.1016\/S1470-2045(19)30167-6"},{"key":"522_CR7","doi-asserted-by":"crossref","unstructured":"Nishio M, Barlesi F, West H, Ball S, Bordoni R, Cobo M, et al. Atezolizumab plus chemotherapy for first-line treatment of nonsquamous NSCLC: results from the randomized phase 3 IMpower132 trial. J Thorac Oncol. 2021;16(4):653\u2013664. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S155608642031100X.","DOI":"10.1016\/j.jtho.2020.11.025"},{"key":"522_CR8","doi-asserted-by":"crossref","unstructured":"Socinski MA, Nishio M, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D et al. IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC. J Thorac Oncol. 2021;16(11):1909\u20131924. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1556086421023224.","DOI":"10.1016\/j.jtho.2021.07.009"},{"key":"522_CR9","doi-asserted-by":"publisher","unstructured":"Pillai RN, Behera M, Owonikoko TK, Kamphorst AO, Pakkala S, Belani CP, et al. Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: a systematic analysis of the literature. Cancer. 2018;124(2):271\u2013277. Available from: https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/full\/https:\/\/doi.org\/10.1002\/cncr.31043.","DOI":"10.1002\/cncr.31043"},{"key":"522_CR10","doi-asserted-by":"crossref","unstructured":"Chen DS, Irving BA, Hodi FS. Molecular pathways: next-generation immunotherapy\u2014inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res. 2012;18(24):6580-7. Available from: https:\/\/aacrjournals.org\/clincancerres\/article\/18\/24\/6580\/181547\/Molecular-Pathways-Next-Generation-Immunotherapy.","DOI":"10.1158\/1078-0432.CCR-12-1362"},{"key":"522_CR11","doi-asserted-by":"crossref","unstructured":"Meirson T, Asher N, Bomze D, Markel G. Safety of BRAF\u2009+\u2009MEK inhibitor combinations: severe adverse event evaluation. Cancers (Basel). 2020;12(6):1650. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7352287\/.","DOI":"10.3390\/cancers12061650"},{"key":"522_CR12","doi-asserted-by":"crossref","unstructured":"Matsumoto J, Iwata N, Watari S, Ushio S, Shiromizu S, Takeda T, et al. Adverse events of axitinib plus pembrolizumab versus lenvatinib plus pembrolizumab: a pharmacovigilance study in food and drug administration adverse event reporting system. Eur Urol Focus. 2023 Jan;9(1):141\u2013144. Available from: https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S240545692200164X?via%3Dihub.","DOI":"10.1016\/j.euf.2022.07.003"},{"key":"522_CR13","doi-asserted-by":"crossref","unstructured":"Oun R, Moussa YE, Wheate NJ. The side effects of platinum-based chemotherapy drugs: a review for chemists. Dalton Trans. 2018;47(19):6645\u20136653. Available from: https:\/\/pubs.rsc.org\/en\/content\/articlelanding\/2018\/dt\/c8dt00838h.","DOI":"10.1039\/C8DT00838H"},{"key":"522_CR14","doi-asserted-by":"publisher","unstructured":"Poto R, Troiani T, Criscuolo G, Marone G, Ciardiello F, Tocchetti CG, et al. Holistic approach to immune checkpoint inhibitor-related adverse events. Front Immunol. 2022 Mar 30:13:804597. Available from: https:\/\/www.frontiersin.org\/journals\/immunology\/articles\/https:\/\/doi.org\/10.3389\/fimmu.2022.804597\/full.","DOI":"10.3389\/fimmu.2022.804597\/full"},{"key":"522_CR15","doi-asserted-by":"crossref","unstructured":"Watanabe T, Yamaguchi Y. Cutaneous manifestations associated with immune checkpoint inhibitors. Front Immunol. 2023 Feb 20: 14:1071983. Available from: https:\/\/www.frontiersin.org\/journals\/immunology\/articles\/10.3389\/fimmu.2023.1071983\/full.","DOI":"10.3389\/fimmu.2023.1071983"},{"key":"522_CR16","doi-asserted-by":"crossref","unstructured":"Alves RC, Fernandes RP, Eloy JO, Salgado HRN, Chorilli M. Characteristics, properties and analytical methods of paclitaxel: a review. Crit Rev Anal Chem. 2018; 48(2):110\u2013118. Available from: https:\/\/www.tandfonline.com\/doi\/10.1080\/10408347.2017.1416283?url_ver=Z39.88-2003%26_id=ori:rid:crossref.org%26_dat=cr_pub%20%200pubmed.","DOI":"10.1080\/10408347.2017.1416283"},{"key":"522_CR17","doi-asserted-by":"crossref","unstructured":"Shord SS, Bressler LR, Tierney LA, Cuellar S, George A. Understanding and managing the possible adverse effects associated with bevacizumab. Am J Health Syst Pharm. 2009;66(11):999\u20131013. Available from: https:\/\/academic.oup.com\/ajhp\/article-abstract\/66\/11\/999\/5130205?redirectedFrom=fulltext&login=true.","DOI":"10.2146\/ajhp080455"},{"key":"522_CR18","doi-asserted-by":"crossref","unstructured":"Singh SK, Mahler HC, Hartman C, Stark CA. Are injection site reactions in monoclonal antibody therapies caused by polysorbate excipient degradants? J Pharm Sci. 2018;107(11):2735\u20132741. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0022354918304519?via%3Dihub.","DOI":"10.1016\/j.xphs.2018.07.016"},{"key":"522_CR19","doi-asserted-by":"crossref","unstructured":"Raithel M, Matek M, Baenkler HW, Jorde W, Hahn EG. Mucosal histamine content and histamine secretion in Crohn\u2019s disease, ulcerative colitis and allergic enteropathy. Int Arch Allergy Immunol. 1995;108(2):127\u2009\u2013\u200933. Available from: https:\/\/karger.com\/iaa\/article-abstract\/108\/2\/127\/163810\/Mucosal-Histamine-Content-and-Histamine-Secretion?redirectedFrom=fulltext.","DOI":"10.1159\/000237129"},{"key":"522_CR20","doi-asserted-by":"publisher","unstructured":"Garc\u00eda-Mart\u00edn E, Garc\u00eda-Menaya J, S\u00e1nchez B, Mart\u00ednez C, Rosendo R, Ag\u00fandez JAG, et al. Polymorphisms of histamine-metabolizing enzymes and clinical manifestations of asthma and allergic rhinitis. Clin Exp Allergy. 2007;37(8):1175-82. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/https:\/\/doi.org\/10.1111\/j.1365-2222.2007.02769.x.","DOI":"10.1111\/j.1365-2222.2007.02769.x"},{"key":"522_CR21","unstructured":"O\u2019Reilly M, Mellotte G, Ryan B, O\u2019Connor A. Gastrointestinal side effects of cancer treatments. Ther Adv Chronic Dis. 2020;27:11:2040622320970354. Available from: https:\/\/journals.sagepub.com\/doi\/10.1177\/2040622320970354?url_ver=Z39.88-2003%26_id=ori:rid:crossref.org%26_dat=cr_pub%20%200pubmed."},{"key":"522_CR22","doi-asserted-by":"crossref","unstructured":"Som A, Mandaliya R, Alsaadi D, Farshidpour M, Charabaty A, Malhotra N, et al. Immune checkpoint inhibitor-induced colitis: a comprehensive review. World J Clin Cases. 2019;7(4):405\u2013418. Available from: https:\/\/www.wjgnet.com\/2307-8960\/full\/v7\/i4\/405.htm.","DOI":"10.12998\/wjcc.v7.i4.405"},{"key":"522_CR23","doi-asserted-by":"crossref","unstructured":"Xia R, Zhang X. Neutropenic enterocolitis: a clinico-pathological review. World J Gastrointest Pathophysiol. 2019;10(3):36\u201341. Available from: https:\/\/www.wjgnet.com\/2150-5330\/full\/v10\/i3\/36.htm.","DOI":"10.4291\/wjgp.v10.i3.36"},{"key":"522_CR24","unstructured":"Gadducci A, Gargini A, Palla E, Fanucchi A, Genazzani AR. Neutropenic enterocolitis in an advanced epithelial ovarian cancer patient treated with paclitaxel\/platinum-based chemotherapy: a case report and review of the literature. Anticancer Res. 2005 May-Jun;25(3c):2509-13. Available from: https:\/\/ar.iiarjournals.org\/content\/25\/3C\/2509.long."},{"key":"522_CR25","doi-asserted-by":"crossref","unstructured":"Buchinger K, Stahel R, Niggemeier V, Gubler C, Franzen D. Pemetrexed-induced neutropenic enteritis and severe cutaneous hyperpigmentation in a patient with malignant pleural mesothelioma. Lung Cancer. 2013;80(3):347-9. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0169500213001049?via%3Dihub.","DOI":"10.1016\/j.lungcan.2013.02.019"},{"key":"522_CR26","doi-asserted-by":"crossref","unstructured":"Jacob J, Dannenhoffer J, Rutter A. Acute kidney injury. Prim Care. 2020;47(4):571\u2013584. Available from: https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0095454320300622?via%3Dihub.","DOI":"10.1016\/j.pop.2020.08.008"},{"key":"522_CR27","doi-asserted-by":"crossref","unstructured":"Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, Pawel JV, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255\u2013265. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S014067361632517X?via%3Dihub.","DOI":"10.1016\/S0140-6736(16)32517-X"},{"key":"522_CR28","doi-asserted-by":"crossref","unstructured":"Xipell M, Victoria I, Hoffmann V, Villarreal J, Garc\u00eda-Herrera A, Reig O, et al. Acute tubulointerstitial nephritis associated with atezolizumab, an anti-programmed death-ligand 1 (pd-l1) antibody therapy. Oncoimmunology. 2018; 7(7):e1445952. Available from: https:\/\/www.tandfonline.com\/doi\/10.1080\/2162402X.2018.1445952?url_ver=Z39.88-2003%26_id=ori:rid:crossref.org%26_dat=cr_pub%;20%200pubmed#abstract.","DOI":"10.1080\/2162402X.2018.1445952"},{"key":"522_CR29","doi-asserted-by":"crossref","unstructured":"Y\u0131lmaz A, Mirili C, Bilici M, Tekin SB. Possible atezolizumab-associated acute kidney injury and immune thrombocytopenia. J Oncol Pharm Pract. 2020;26(7):1791\u20131794. Available from: https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155220913081?url_ver=Z39.88-2003%26_id=ori:rid:crossref.org%26_dat=cr_pub%20%200pubmed.","DOI":"10.1177\/1078155220913081"},{"key":"522_CR30","doi-asserted-by":"crossref","unstructured":"Araki R, Tsukada Y, Hishinuma R, Keira T, Kato K, Tanaka T. Identification of the risk factors for severe neutropenia induced by pemetrexed plus carboplatin chemotherapy. Jpn. J. Pharm. Health Care Sci. 2016;42(4):278\u2013285. Available from: https:\/\/www.jstage.jst.go.jp\/article\/jjphcs\/42\/4\/42_278\/_article\/-char\/ja.","DOI":"10.5649\/jjphcs.42.278"},{"key":"522_CR31","doi-asserted-by":"publisher","unstructured":"Mita AC, Sweeney CJ, Baker SD, Goetz A, Hammond LA, Patnaik A, et al. Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. J Clin Oncol. 2006;24(4):552\u2009\u2013\u200962. Available from: https:\/\/doi.org\/10.1200\/JCO.2004.00.9720?url_ver=Z39.88-2003%26_id=ori:rid:crossref.org%26_dat=cr_pub%;20%200pubmed.","DOI":"10.1200\/JCO.2004.00.9720?url_ver=Z39.88-2003%26_id=ori:rid:crossref.org%26_dat=cr_pub%;20%200pubmed"},{"key":"522_CR32","doi-asserted-by":"crossref","unstructured":"Rouw ND, Boosman RJ, Huitema ADR, Hilbrands LB, Svensson EM, Derijks HJ, et al. Rethinking the application of pemetrexed for patients with renal impairment: a pharmacokinetic analysis. Clin Pharmacokinet. 2021;60(5):649\u2013654. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8113206\/.","DOI":"10.1007\/s40262-020-00972-1"},{"key":"522_CR33","doi-asserted-by":"publisher","unstructured":"Launay-Vacher V, Etessami R, Janus N, Spano JP, Ray-Coquard I, Oudard S, et al. Lung cancer and renal insufficiency: prevalence and anticancer drug issues. Lung. 2009 Jan-Feb;187(1):69\u201374. Available from: https:\/\/link.springer.com\/article\/https:\/\/doi.org\/10.1007\/s00408-008-9123-5.","DOI":"10.1007\/s00408-008-9123-5"},{"key":"522_CR34","doi-asserted-by":"crossref","unstructured":"Zhu X, Wu S, Dahut WL, Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis. 2007;49(2):186\u2009\u2013\u200993. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0272638606018336?via%3Dihub.","DOI":"10.1053\/j.ajkd.2006.11.039"},{"key":"522_CR35","doi-asserted-by":"crossref","unstructured":"Abbate M, Zoja C, Remuzzi G. How does proteinuria cause progressive renal damage? J Am Soc Nephrol. 2006;17(11):2974-84. Available from: https:\/\/journals.lww.com\/jasn\/abstract\/2006\/11000\/how_does_proteinuria_cause_progressive_renal.9.aspx.","DOI":"10.1681\/ASN.2006040377"},{"key":"522_CR36","doi-asserted-by":"publisher","unstructured":"Zen Y, Chen YY, Jeng YM, Tsai HW, Yeh MM. Immune-related adverse reactions in the hepatobiliary system: second-generation check-point inhibitors highlight diverse histological changes. Histopathology. 2020;76(3):470\u2013480. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/https:\/\/doi.org\/10.1111\/his.14000.","DOI":"10.1111\/his.14000"},{"key":"522_CR37","doi-asserted-by":"crossref","unstructured":"Ramadori G, Cameron S. Effects of systemic chemotherapy on the liver. Ann Hepatol. 2010 Apr-Jun;9(2):133\u2009\u2013\u200943. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1665268119316515?via%3Dihub.","DOI":"10.1016\/S1665-2681(19)31651-5"},{"key":"522_CR38","doi-asserted-by":"publisher","unstructured":"Yao L, Zhang J, Jin J, Li H, Li L, Han X, et al. An analysis of the efficacy and safety of compound glycyrrhizin injections in the treatment of drug-induced liver injury using a nationwide database. Int J Clin Pharm. 2022;44(3):731\u2013740. Available from: https:\/\/link.springer.com\/https:\/\/doi.org\/10.1007\/s11096-022-01402-x.","DOI":"10.1007\/s11096-022-01402-x"},{"key":"522_CR39","doi-asserted-by":"crossref","unstructured":"Beuers U. Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat Clin Pract Gastroenterol Hepatol. 2006;3(6):318\u2009\u2013\u200928. Available from: https:\/\/www.nature.com\/articles\/ncpgasthep0521.","DOI":"10.1038\/ncpgasthep0521"},{"key":"522_CR40","doi-asserted-by":"publisher","unstructured":"Gatzen M, Pausch J. Treatment of cholestatic liver diseases. Med Klin (Munich). 2002;97(3):152-9. Available from: https:\/\/link.springer.com\/article\/https:\/\/doi.org\/10.1007\/s00063-002-1139-7.","DOI":"10.1007\/s00063-002-1139-7"},{"key":"522_CR41","doi-asserted-by":"publisher","unstructured":"Long K, Suresh K. Pulmonary toxicity of systemic lung cancer therapy. Respirology. 2020 Nov: 25 Suppl 2:72\u201379. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/https:\/\/doi.org\/10.1111\/resp.13915.","DOI":"10.1111\/resp.13915"},{"key":"522_CR42","doi-asserted-by":"crossref","unstructured":"Zhang Q, Tang L, Zhou Y, He W, Li W. Immune checkpoint inhibitor-associated pneumonitis in non-small cell lung cancer: current understanding in characteristics, diagnosis, and management. Front Immunol. 2021 May;28:12:663986. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8195248\/.","DOI":"10.3389\/fimmu.2021.663986"},{"key":"522_CR43","doi-asserted-by":"crossref","unstructured":"Waters MJ, Sukumaran S, Karapetis CS. Pemetrexed-induced interstitial pneumonitis: a case study and literature review. World J Oncol. 2014;5(5\u20136):232\u2013236. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC5649774\/.","DOI":"10.14740\/wjon845w"},{"key":"522_CR44","doi-asserted-by":"crossref","unstructured":"Otoshi R, Sekine A, Hagiwara E, Okudela K, Katano T, Aiko N, et al. Pemetrexed-induced interstitial lung disease mimicking hypersensitivity pneumonia: a pathologically proven case. Intern Med. 2019;58(18):2679\u20132682. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC6794179\/.","DOI":"10.2169\/internalmedicine.2548-18"}],"container-title":["Journal of Pharmaceutical Health Care and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-025-00522-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40780-025-00522-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-025-00522-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T13:40:20Z","timestamp":1768225220000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40780-025-00522-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,6]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["522"],"URL":"https:\/\/doi.org\/10.1186\/s40780-025-00522-6","relation":{},"ISSN":["2055-0294"],"issn-type":[{"value":"2055-0294","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,6]]},"assertion":[{"value":"8 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2"}}